Literature DB >> 22487894

Hypogonadism related to crizotinib therapy: implications for patient care.

Suresh S Ramalingam, Alice T Shaw.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22487894     DOI： 10.1002/cncr.27561

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  3 in total

1.  Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients.

Authors:  Andrew J Weickhardt; Robert C Doebele; W Thomas Purcell; Paul A Bunn; Ana B Oton; Micol S Rothman; Margaret E Wierman; Tony Mok; Sanjay Popat; Julie Bauman; Jorge Nieva; Silvia Novello; Sai-Hong Ignatius Ou; D Ross Camidge
Journal:  Cancer       Date:  2013-04-12       Impact factor: 6.860

Review 2.  Crizotinib: A comprehensive review.

Authors:  Arvind Sahu; Kumar Prabhash; Vanita Noronha; Amit Joshi; Saral Desai
Journal:  South Asian J Cancer       Date:  2013-04

3.  Crizotinib, an Effective Agent in ROS1-Rearranged Adenocarcinoma of Lungs: A Case Report.

Authors:  Julie Mariam Joshua; Salima Kd; Pavithran K; Meenu Vijayan
Journal:  Clin Med Insights Case Rep       Date:  2018-01-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.